Why is India’s Child Vaccination Budget Not Being Spent?

The Funding Paradox in India’s National Immunisation Efforts

Recent RTI data indicates a surprising trend regarding National Immunisation Programme funding in India. Although the government allocates thousands of crores annually, a significant portion of these funds remains unspent. Consequently, medical professionals and public health experts are questioning the efficiency of implementation across various states and Union Territories. Because child health remains a top priority, understanding these financial bottlenecks is essential for improving future healthcare delivery for infants and children.

Dissecting National Immunisation Programme funding Discrepancies

In the fiscal year 2023-24, the government approved approximately Rs 3,232 crore for the program. However, states utilized only about Rs 2,250 crore during that period. Furthermore, the expenditure dropped further in 2024-25 to roughly Rs 1,971 crore against a sanction of Rs 3,186 crore. Even though allocations rose to over Rs 3,400 crore for 2025-26, provisional data shows that only Rs 1,060 crore was spent by December. These figures suggest that while the intent to fund is strong, the administrative capacity to deploy these resources faces hurdles.

These financial gaps persist despite the massive scale of the operation. Currently, the program vaccinates between 2.3 crore and 2.5 crore children every year. Therefore, while financial management shows lags, the clinical reach remains substantial. Vaccines are sourced from a robust network of manufacturers including the Serum Institute of India and Bharat Biotech. This infrastructure ensures that children receive protection against polio, measles, and hepatitis B regardless of the budgetary underspending. For those interested in the clinical standards of pediatric care, pursuing a Certification Course In Paediatrics can provide deeper insights into managing child health programs.

Progress in Immunisation Coverage and Implementation Gaps

Fortunately, full immunisation coverage has shown positive trends. Specifically, coverage improved from 88.2% in 2021-22 to 98.1% in 2024-25. Nevertheless, experts like RTI activist Amit Gupta emphasize the need for transparency. He suggests expanding the scope to include vaccines for influenza and typhoid. Additionally, the RTI response highlighted fragments in data record-keeping. For instance, gender-wise vaccination figures were unavailable from the primary division. This lack of centralized data could hinder targeted public health interventions in the future.

Frequently Asked Questions

Q1: Why is there a significant gap in the National Immunisation Programme funding utilization?

The gap often arises due to fragmented record-keeping and delays in state-level financial monitoring reports. Despite high allocations, the actual expenditure consistently lags behind sanctioned amounts due to administrative hurdles.

Q2: How has India’s full immunization coverage changed recently?

As of 2024-25, India has achieved a high full immunisation coverage rate of 98.1%. This reflects a steady and significant increase from the 88.2% recorded during the 2021-22 period. Those looking to specialize in post-graduate training in pediatrics can further support these national health goals.

Q3: Which diseases are covered under the free vaccination program?

The program provides free vaccines to protect children against several major diseases. These include polio, measles, and hepatitis B, among other life-threatening illnesses provided through the public health network.

References

1. Big share of funds for kids’ jabs not spent: RTI data – ETHealthworld
2. Ministry of Health and Family Welfare – National Immunisation Schedule Guidelines
3. National Health Mission – State-wise Financial Monitoring Reports 2024

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.